| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
XBiotech Inc.$2.29
0 (0%)
D 35Pipeline Score Fair Value Biotech · Clinical
Market Cap
74.09 M
EPS
-1.32
P/E Ratio
-
Value Trade
107.09 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.21 M
Operating CF
-8.97 M
Total Assets
139.84 M
Total Liabilities
4.82 M
Equity
135.02 M
D/E Ratio
12,345
-1.62 %
Week
-3.57 %
1 Month
2.1 %
3 Month
6.58 %
6 Month
-86.28 %
5 Year
-89.43 %
All Time
Cash Data
Cash Position
115.46 M
Monthly Burn
2.99 M
Runway
36.9 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
31.23 K
52 Week Range
2.09 - 3.61
% held by Insiders
24.33 %
% held by Institutions
6.58 %
Enterprise Value
-41.37 M
Total Shares
30.47 M
Short %
1.66 %
Float Shares
16.58 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $130M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.8x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 911)
Percentile RankXBiotech Inc. faces pipeline headwinds (35/100), with $518M risk-adjusted pipeline value, led by vilamakitug in Axial Spondyloarthritis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vilamakitug Small molecule | Axial Spondyloarthritis | Phase 2 | NCT06526377 | 14% | $239M | NOT YET_RECRUITING | 150 | - | C (58) | Sep 1, 2028 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XBIT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XBIT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XBITXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
XBiotech has announced the successful completion of the FDA's 30-day review of its IND application for the Phase II V-SPINE study, which will evaluate vilamakitug in patients with active axial spondyloarthritis. The study aims to enroll 150 participants and assess the drug's efficacy and safety. This marks a significant step in addressing the unmet medical needs in this patient population.
Read more →XBITXBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
XBiotech has announced the successful FDA review of its IND application for the V-SPINE study, a Phase II trial evaluating vilamakitug in patients with active axial spondyloarthritis. The study will involve 150 participants and aims to assess the drug's efficacy and safety. The trial is set to proceed with patient recruitment in the U.S., marking a significant step in XBiotech's rheumatology program.
Read more →XBITXBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis
XBiotech Inc. has announced the FDA's approval of its IND application for the V-SPINE Phase II study, which will evaluate the efficacy and safety of Vilamakitug in treating active axial spondyloarthritis. The study will involve 150 participants and aims to determine the percentage achieving an ASAS40 response by week 16. This marks a significant step in XBiotech's rheumatology program.
Read more →XBITXBiotech Announces Outcome of EMA's Oral Explanation Meeting
XBiotech Announces Outcome of EMA's Oral Explanation Meeting AUSTIN, Texas, April 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative "trend" vote after meeting with the Company to discuss the "Day
Read more →XBITCorporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity
Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substantial risks and uncertainties
Read more →XBITXBiotech Closes Initial Public Offering Austin, TX
XBiotech Closes Initial Public Offering Austin, TX April 17, 2015 XBiotech Inc. (NASDAQ: XBIT), a leading developer of next-generation therapeutic antibodies, announced today the closing of its initial public offering of 4,000,000 shares of its common stock at an initial public
Read more →Competitive Position
How XBIT ranks across every disease it competes inCompetitive Position is a premium feature
See how XBIT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial